|
Post by loparn on May 15, 2020 6:58:19 GMT
Immunicum - from a interview (see link below) with COO Sijme Zeilemaker. "How does this approach differ from some of the others presented at the panel discussion? – The panel included approaches to enhanced tumour radiation, an allogeneic mixed cell therapy, and bispecific antibodies. Each is able to address parts of the cancer immunity cycle, i.e. all elements of the immune system needed to recognize and attack cancer, by for example inducing immunogenic tumour cell death, activating Natural Killer (NK) cells, or stimulating the expansion of immune cells. – Unfortunately, cancer has established itself with multiple defence mechanisms, and only targeting one such mechanism while leaving open other pathways allows for cancer evasion and escape. Immunicum’s ilixadencel primarily addresses this by focusing on a more complete mechanism of priming the immune system: by injecting inflammatory DCs in the immunosuppressive environment of the tumour and inducing a cascade of immune cells, such as NK cells, bystander DCs and killer T cells, to counteract the tumour cells." www.biostock.se/2020/05/immunicum-i-rampljuset-pa-cancer-progress-konferensen/
|
|